NASDAQ : LIMN
Liminatus Pharma, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.82 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.79M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.79M |
| Enterprise Value | 2.21M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.34M |
| Shares Outstanding | 1.34M |
| Shares Change (YoY) | +82.95% |
| Shares Change (QoQ) | +34.44% |
| Owned by Insiders (%) | 12.21% |
| Owned by Institutions (%) | 5.30% |
| Float | 1.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 10.50 |
| P/TBV Ratio | 12.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.12 |
| Quick Ratio | 0.99 |
| Debt / Equity | 4.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -53.78 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -95.65% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -1,119.03% |
| Weighted Average Cost of Capital (WACC) | 7.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$12.52M |
| Employee Count | 1 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.75 |
| 52-Week Price Change | -96.03% |
| 50-Day Moving Average | 3.66 |
| 200-Day Moving Average | 11.10 |
| Relative Strength Index (RSI) | 34.41 |
| Average Volume (20 Days) | 25,487 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 39,632 |
| Short Previous Month | 44,566 |
| Short % of Shares Out | 2.95% |
| Short % of Float | 3.87% |
| Short Ratio (days to cover) | 1.73 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -4.07M |
| Pretax Income | -12.52M |
| Net Income | -12.52M |
| EBITDA | -4.06M |
| EBIT | -4.07M |
| Earnings Per Share (EPS) | -$18.06 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.02M |
| Total Debt | 1.44M |
| Net Cash | 1.57M |
| Net Cash Per Share | $1.17 |
| Equity (Book Value) | 300,612 |
| Book Value Per Share | 0.27 |
| Working Capital | 352,044 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -3.97M |
| Capital Expenditures | -13,108 |
| Depreciation & Amortization | 2,071 |
| Net Borrowing | -1.30M |
| Free Cash Flow | -3.99M |
| FCF Per Share | -$2.97 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -82.95% |
| Shareholder Yield | -82.95% |
| Earnings Yield | -640.45% |
| FCF Yield | -105.23% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 21, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |